Mersana Therapeutics Inc

Mersana Therapeutics — Technical Presentation (September 2021)

32 slides from Mersana Therapeutics's technical presentation, Sep 10, 2021

  1. Slide 1: Interim Data from the Ovarian Cancer Expansion Cohort and Next Steps for UpRi Development Plan

    Interim Data from the Ovarian Cancer Expansion Cohort and Next Steps for UpRi Development Plan September 10, 2021

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer This presentation contains “forward-looking” statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on management’s beliefs and assumptions and on information currently available to management.

  3. Slide 3: Today's Agenda

    Today’s Agenda 3 Topic Speaker • Opening Remarks Anna Protopapas, President & CEO • Interim Data from the Ovarian Cancer Expansion Cohort of the UpRi Phase 1 Study Debra L. Richardson, MD, Associate Professor and Section Chief, Division of Gynecological Oncology at OU Health Stephenson Cancer Center

  4. Slide 4: UpRi: First-in-Class Dolaflexin ADC Targeting NaPi2b

    UpRi: First-in-Class Dolaflexin ADC Targeting NaPi2b Interim Data from the Ovarian Cancer Expansion Cohort of the UpRi Phase 1 Study Debra L. Richardson, MD Associate Professor and Section Chief, Division of Gynecological Oncology at OU Health Stephenson Cancer Center and the Sarah Cannon Research I

  5. Slide 5: Significant Unmet Medical Need in Platinum-Resistant Ovarian Cancer

    Significant Unmet Medical Need in Platinum-Resistant Ovarian Cancer Study Demographics Control Arm Control Arm Performance Forward I ESMO 2019 Annals of Oncology 2021; 32(6):757-765 1 – 3 Prior Median 2 Prior Prior PARPi: 10% Prior Bev: 47% PLD, Topotecan, Weekly Paclitaxel ORR 12% Javelin 200 SGO 2

  6. Slide 6: Design for the Ovarian Cancer Expansion Cohort of the UpRi Phase 1 Study

    Design for the Ovarian Cancer Expansion Cohort of the UpRi Phase 1 Study 6 Ovarian Cancer Cohort • 1-3 prior lines in platinum resistant • 4 prior lines regardless of platinum status • High grade serous histology • Archived tumor and fresh biopsy (if medically feasible) for NaPi2b • Exclusion: prima

  7. Slide 7: Expansion Cohort Experience Across a Range of Doses Allows for Further Optimization of UpRi Profile

    Expansion Cohort Experience Across a Range of Doses Allows for Further Optimization of UpRi Profile 7 36 mg/m2 (N=12) 43 mg/m2 BSA < 1.8 BSA > 1.8 43 mg/m2 (N=39) ~80 mg (N=46) Doses Studied in Expansion 7 0 5 10 15 20 25 30 35 40 45 50 1.4 1.6 1.8 2 2.2+ Dose (mg/m 2 ) 50% of Patients 50% of Patien

  8. Slide 8: Patient Demographics and Disease Characteristics

    Data Cut: June 10, 2021 Patient Demographics and Disease Characteristics 8 Ovarian Cancer Expansion Patients (N = 97) Age; years Median (range) 68 (33, 87) ECOG Performance Status; n (%) 0 1 33 (34) 64 (66) Baseline BSA ≥ 1.8 m2 ≥ 2.2 m2 51 (53) 5 (5) Primary Tumor Type; n (%) Ovarian Fallopian Tube

  9. Slide 9: UpRi Continues to Have a Consistent Tolerability Profile

    No grade ≥ 3 (severe) TRAEs of neutropenia, peripheral neuropathy, or ocular toxicity have been reported UpRi Continues to Have a Consistent Tolerability Profile 9 a b c d aFatigue includes preferred terms of asthenia and fatigue; bAST increase is transient in nature, recovers to baseline or to Grad

  10. Slide 10: Decreased Grade 3+ Treatment Related AEs with Lower Dose

    10 Lower Dose 36 mg/m2 Intermediate Dose ~80 mg Higher Dose 43 mg/m2 > Grade 3 Fatigue 1 (8%) 6 (13%) 9 (23%) > Grade 3 Increased AST 1 (8%) 16 (35%) 16 (41%) > Grade 3 Pneumonitis 0 (0%) 0 (0%) 4* (10%) Decreased Grade 3+ Treatment Related AEs with Lower Dose Data Cut: June 10, 2021 * 2 cases of Gr

  11. Slide 11: Observed Consistent Tolerability Profile with Limited Discontinuations due to TRAE

    Observed Consistent Tolerability Profile with Limited Discontinuations due to TRAE 11 Dose modification due to Treatment-Related Adverse Events (TRAEs): • Of the 97 patients, 43 (44%) had dose delay, reduction, and/or discontinuation due to a TRAE – Dose reductions due to TRAEs occurred in 27 (28%)

  12. Slide 12: Consistent Activity Observed in Heavily-Pretreated Ovarian Cancer

    Consistent Activity Observed in Heavily-Pretreated Ovarian Cancer 12 Best Response in Evaluable Patients with Ovarian Cancer (n = 75) NaPi2b High (TPS>75) NaPi2b Low (TPS<75) Not Yet Determined NaPi2b All Patients N 38 23 14 75 CR 2 (5) 0 0 2 (3) PR 11 (29) 2 (9) 2 (14) 15 (20) uPR 1 (3) 0 2 (14) 3

  13. Slide 13: Similar Efficacy Across the Three Dose Levels, with Trend to Higher Efficacy with Lower Dose

    Similar Efficacy Across the Three Dose Levels, with Trend to Higher Efficacy with Lower Dose 50% 41% 15% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Lower Dose: 36 mg/m2 Intermediate Dose: ~80 mg Higher Dose: 43 mg/m2 13 Confirmed ORR with 95% Confidence Interval NaPi2b High, RECIST-Evaluable (N=38)

  14. Slide 14: Two-Thirds of Patients Had Reductions in Target Tumor Lesions

    Two-Thirds of Patients Had Reductions in Target Tumor Lesions 14 Maximum % Change from Baseline in Target Lesions in Evaluable Patients with Ovarian Cancer (n=73*) 2 pts excluded as post-baseline tumor measurement shows "Not Measurable", yet "PD" was assigned by Investigator in the response dataset

  15. Slide 15: Trend to Longer Time on Study with High NaPi2b Expression

    Trend to Longer Time on Study with High NaPi2b Expression 15 Abbreviations: CR = complete response; PR = partial response; uPR = unconfirmed PR; High = High NaPi2b Expression; Low = Low NaPi2b Expression; ND = NaPi2b Expression not yet determined or tissue not available High Low ND NaPi2b Expression

  16. Slide 16: Median Duration of Response Consistent at ~5 Months in Patients with High NaPi2b Expression

    Median Duration of Response Consistent at ~5 Months in Patients with High NaPi2b Expression 16 Duration of Response in Patients with NaPi2b High Ovarian Cancer (n=13) *The median duration of response for NaPi2b Low and NaPi2b not yet determined expression is 3.9 months and 3.7 months, respectively.

  17. Slide 17: Partial Response in a Patient with Ovarian Cancer Treated at 36 mg/m2

    Partial Response in a Patient with Ovarian Cancer Treated at 36 mg/m2 for a Total of 9 Cycles 17 • 66-year-old patient with BRCA1/2 negative high-grade serous ovarian cancer • NaPi2b High (TPS>75) • 4 prior lines of systemic therapies including carboplatin/taxol/bevacizumab; carboplatin/doxil with P

  18. Slide 18: Conclusions: UpRi Expansion in Ovarian Cancer

    Conclusions: UpRi Expansion in Ovarian Cancer 18 • In this updated analysis of patients with heavily-pretreated ovarian cancer, UpRi continued to be generally well-tolerated with a consistent profile – no severe neutropenia, peripheral neuropathy, or ocular toxicity • Consistent antitumor activity o

  19. Slide 19: We thank the patients, their families and caregivers for their contribution to this study

    We thank the patients, their families and caregivers for their contribution to this study UNTED STATES Allegheny Health Network, Pittsburgh, PA Arizona Oncology Associates, Tucson, AZ Avera Cancer Institute – Sioux Falls, SD Billings Clinic, Billings, MT Dana Farber Cancer Institute, Boston, MA Emor

  20. Slide 20: Next Steps for UpRi Development Plan

    Next Steps for UpRi Development Plan

  21. Slide 21: Increasing Dose Beyond the Optimal Threshold May Add Incremental Toxicity without Incremental Efficacy

    Increasing Dose Beyond the Optimal Threshold May Add Incremental Toxicity without Incremental Efficacy 21 • Further analysis utilizing population PK models confirmed the efficacy and safety findings showing the association between increasing exposure and G3+ adverse events, including pneumonitis • P

  22. Slide 22: Action Plan to Implement Learnings from Expansion Cohort Data Set

    Action Plan to Implement Learnings from Expansion Cohort Data Set 22 • Data set from expansion cohort supports differentiated efficacy and tolerability profile • Analysis of data combined with population PK modeling identifies the opportunity to further improve UpRi profile • New UPLIFT Dose: 36 mg/

  23. Slide 23: UP-NEXT: UpRi Monotherapy vs. Placebo as Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer

    UP-NEXT: UpRi Monotherapy vs. Placebo as Maintenance in Platinum- Sensitive Recurrent Ovarian Cancer

  24. Slide 24: Despite Bevacizumab and PARPi Options, Significant Unmet Need Remains for New Maintenance Agents

    Despite Bevacizumab and PARPi Options, Significant Unmet Need Remains for New Maintenance Agents 24 • Patients poorly served by current maintenance agents need additional options. Watch & wait remains an option in guidelines – 80% of patients without BRCA mutation (e.g., HRP, HRD) – Co-morbidities (

  25. Slide 25: UP-NEXT/GOG-3049: Phase 3 Study of UpRi Monotherapy Maintenance vs Placebo

    UP-NEXT/GOG-3049: Phase 3 Study of UpRi Monotherapy Maintenance vs Placebo in Platinum-Sensitive Recurrent OC 25 Key Enrollment Criteria: - Platinum-sensitive recurrence, following platinum induction - NaPi2b High biomarker selection by TPS>75 - 1 – 3 prior platinum-based regimes - Prior PARPi thera

  26. Slide 26: UP-NEXT Key Differentiators

    UP-NEXT Key Differentiators 26 Frontline Therapy Platinum- Sensitive Recurrence Platinum- Resistant Recurrence Maintenance UPLIFT UPGRADE UP-NEXT • Platinum-Sensitive Population – Earlier in disease than UPLIFT population – Opportunity to be first ADC in earlier lines and platinum-sensitive disease

  27. Slide 27: Closing Remarks

    Closing Remarks

  28. Slide 28: Data Set Supports UpRi Profile and UPLIFT Registration Strategy

    UpRi Profile 28 Meaningful Activity and Durable in Heavily-Pretreated Patients >30% ORR with CRs in NaPi2b High Ovarian Cancer Consistent Tolerability Profile No Severe Neutropenia, Ocular Toxicity, or Peripheral Neuropathy Robust, Predictive, and Reproducible Diagnostic Tumor Proportion Score > 75

  29. Slide 29: Increasing Market Potential

    29 INCREASING MARKET POTENTIAL . Phase 3 Study in Platinum- Sensitive Maintenance Phase 1 / 2 Combinations to Enable Pivotal Development UPGRADE Umbrella Combo Starting with Platinum UP-NEXT UPLIFT Single-Arm Registration Strategy in Platinum- Resistant Disease An Opportunity to Deliver a Potentiall

  30. Slide 30: Future Development Opportunities in Platinum-Sensitive, Platinum-Resistant, Monotherapy, Combination

    • 22,000 newly diagnosed ovarian cancer patients annually • Plus, fallopian tube and primary peritoneal cancers treated in the same algorithm • With a median survival 5 years from diagnosis • 80% relapse following frontline therapy • And 14,000 deaths per year 30 Frontline Therapy Platinum- Sensitiv

  31. Slide 31: Multiple Value-Drivers Across UpRi, Pipeline, and Platforms

    31 Multiple Value-Drivers Across UpRi, Pipeline, and Platforms Build UpRi as a Foundational Medicine in Ovarian Cancer Build Out Pipeline UPLIFT UP-NEXT UPGRADE to Enable Combos UpRi NSCLC XMT-1592 (NaPi2b Dolasynthen) XMT-1660 (B7-H4 Dolasynthen) XMT-2056 (Immuno- synthen) Dolaflexin Dolasynthen Im

  32. Slide 32: Q&A

    Q&A

Mersana Therapeutics — Technical Presentation (September 2021) on 6ix